SG&A at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s SG&A?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported SG&A of $63.59M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s SG&A increased by 62.7% year-over-year, from $39.09M to $63.59M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s SG&A has grown at a 29.9% compound annual growth rate (CAGR), from $68.49M to $194.94M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.